Autopsy report · NCT05573035

A Study to Investigate LYL845 in Adults With Solid Tumors

“Pipeline Reprioritization”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 2 years 1 month before it stopped.
• 39 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Lyell Immunopharma, Inc.

Sponsor type

Industry

Conditions

Melanoma; Non-small Cell Lung Cancer; Colorectal Cancer

Interventions

LYL845

Participants

39

Sites

18

Countries

United States

Trials that died the same way

• CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
  “Sponsor Decision - Pipeline Reprioritization” (68% match in meaning)
• IMM60 and Pembrolizumab in Melanoma and NSCLC
  “Prioritization of other pipeline assets. No safety or efficacy issues were observed.” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.